Comparing SG&A Expenses: Amgen Inc. vs TG Therapeutics, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Biotech Giants

In the ever-evolving landscape of biotechnology, understanding the financial strategies of industry leaders is crucial. Amgen Inc. and TG Therapeutics, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, Amgen's SG&A expenses have shown a steady increase, peaking at approximately $6.2 billion in 2023, reflecting a 31% rise since 2014. This growth underscores Amgen's expansive operational strategies and market reach.
Conversely, TG Therapeutics, Inc., a smaller player, has seen its SG&A expenses fluctuate more dramatically, with a notable spike in 2021, reaching $152 million, a staggering 1,100% increase from 2014. This surge highlights TG Therapeutics' aggressive push into the market, likely driven by increased marketing and administrative efforts. These trends offer valuable insights into the strategic priorities and market dynamics of these biotech firms.